Journal of Cancer Policy最新文献

{"title":"A National Cancer Plan for England: remember the needs of people in rural and coastal areas.","authors":"David Nelson, Mark Lawler, Ros Kane, Ben Pickwell-Smith, Samuel Cooke, Ava Harding-Bell, Kathie McPeake, Lynn Calman, Peter Selby","doi":"10.1016/j.jcpo.2024.100553","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100553","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100553"},"PeriodicalIF":2.0,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking barriers: The impact of telemedicine on improving soft tissue and bone tumor management in Armenia.","authors":"Ruzanna Papyan, Shushan Hovsepyan, Julieta Hoveyan, Saten Hovhannisyan, Tatev Arakelyan, Gevorg Tamamyan, Lilit Sargsyan, Lusine Hakobyan, Levon Davtyan, Armine Lazaryan, Davit Dallakyan, Narek Manukyan, Armen Mkhitaryan, Nelli Grigoryan, Sybille Perkowski, Birgit Froehlich, Andreas Groll, Manfred Schiborr, Katja Glutig, Kai Kroeger, Niklas Deventer, Marieke Mathilda Vaal, Karsten Wiebe, Joerg Haier, Wolfgang Hartmann, Eva Wardelmann, Monika Scheer, Heribert Jürgens","doi":"10.1016/j.jcpo.2024.100530","DOIUrl":"10.1016/j.jcpo.2024.100530","url":null,"abstract":"<p><strong>Purpose: </strong>Musculoskeletal sarcomas are a rare group of malignant neoplasms, accounting for approximately 12 % of all malignant neoplasms among children. Childhood cancer outcomes vary between developed and developing countries due to financial and educational inequalities. Telemedicine programs have a huge impact on the quality of cancer care, helping to optimize resources for better cancer care in a resource-limited setting. In 2019, Armenia established multidisciplinary teams (MDT) with the guidance of international experts via telemedicine, significantly improving patients' management diagnosed with sarcomas.</p><p><strong>Methods: </strong>The musculoskeletal cancer working group, mentored by the University Hospital of Münster (UKM), conducted weekly virtual tumor boards to discuss cases, focusing on the review of pathological and radiological examinations.</p><p><strong>Results: </strong>From August 2019 to December 2023, the musculoskeletal cancer MDT discussed 151 musculoskeletal tumor cases via 74 MDT meetings. Imaging studies of all discussed cases were reviewed, while the review of histology images was performed for 93 % of cases. The pathology review led to changes in previously established diagnoses in eleven cases, which subsequently changed management. These led to altered local control strategies for 32 patients, with 5 requiring treatment abroad, and changes in chemotherapy regimens for 17 patients. Notably, there were no cases of treatment refusal post-implementation, a reduction from the previous 3 % refusal rate.</p><p><strong>Conclusion: </strong>The successful telemedicine initiative, coupled with institutional support, improved the care of patients diagnosed with musculoskeletal tumors. The investment in telemedicine in developing countries not only enhances communications with international and local experts across various disciplines but also significantly improves the handling of patients diagnosed with sarcomas.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100530"},"PeriodicalIF":2.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer in Bulgaria prior implementation of a national breast cancer screening program and certified breast centers.","authors":"Mariela Vasileva-Slaveva, Desislava Kostova-Lefterova, Filip Simeonov, Angel Yordanov, Metodi Metodiev","doi":"10.1016/j.jcpo.2024.100531","DOIUrl":"10.1016/j.jcpo.2024.100531","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer (BC) survival has improved globally in the past years. Eastern Europe is a region with lack of epidemiological data and traditionally lower BC overall survival (OS). We aimed to investigate the epidemiology of BC in Bulgaria between 2012 and 2022 and the readiness of the state for implementing population based organized screening program.</p><p><strong>Methods and materials: </strong>This is a retrospective study of 38 576 invasive BC cases registered in Bulgarian National Cancer Registry. We obtained data from publicly available sources - national institutes and regulatory agencies. We report descriptive statistics of distribution of cases and mammography units among the country and the compared survival of patient's groups.</p><p><strong>Results: </strong>75 % of patients are treated in the 9 biggest cities. They are younger, diagnosed earlier and have significantly better OS than the rest of the patients. Patients over 75 years represent 18.7 % of all. The 211 installed mammography systems can secure the implementation of organized BC screening.</p><p><strong>Discussion: </strong>The survival gap between cities can be due to the limited access to care of older patients living in smaller cities. The model of collaboration between private and state centers can be highly effective in implementing of organized screening since in Bulgaria both can be reimbursed by the National Insurance Fund.</p><p><strong>Conclusion: </strong>Further centralization of care probably would not have such an impact on treatment outcomes as improvement and monitoring the quality of the provided treatment. Organized BC screening in Bulgaria is needed and technically possible step towards improving survival.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100531"},"PeriodicalIF":2.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142819675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-surgical acute care utilization and cost of care among cancer survivors with an ostomy: Findings from three large hospital systems in the United States.","authors":"Daniel Maeng, Rebecca L Hoffman, Virginia Sun, Robert P Sticca, Robert S Krouse","doi":"10.1016/j.jcpo.2024.100534","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100534","url":null,"abstract":"<p><strong>Purpose: </strong>To describe patterns of 6-month total cost of care and acute care utilization among cancer survivors who received ostomy surgeries in 3 large hospital systems in the United States between 2018 and 2022 and to identify reasons for acute care utilization.</p><p><strong>Methods: </strong>A retrospective cohort study using electronic medical records and the corresponding hospital revenue data obtained from 3 geographically diverse hospital systems in the United States was performed. 6-month all-cause post-surgical encounters subsequent to respective ostomy surgery dates were included. Clinical reasons for acute care utilization were captured and examined via available diagnosis codes.</p><p><strong>Results: </strong>Mean six-month total cost of care per patient varied greatly by hospital and by payer type, ranging between $18,000 and $80,000. Inpatient care was the largest driver of these cost, accounting for 70 % of the total cost of care. In the sample, 56 % of the patients experienced one or more post-surgical inpatient admissions over a six-month period. Moreover, 26 % of the acute care events were associated with primary or secondary diagnosis codes potentially attributable to post-surgical ostomy-related complications, accounting for approximately 18 % of the total cost. Patients who received urostomy and/or had metastatic cancer had higher rates of acute care utilization, although statistical significances were not achieved.</p><p><strong>Conclusion: </strong>The results are indicative of significant financial burdens as well as morbidities associated with post-surgical ostomy care that are common across hospital systems. Some of these cost burdens are potentially avoidable with improved ostomy follow-up care.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"100534"},"PeriodicalIF":2.0,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trend of sales revenue by year for top selling cancer drugs in the US and the effect of loss of market exclusivity.","authors":"Myung Sun Kim, Alyson Haslam, Vinay Prasad","doi":"10.1016/j.jcpo.2024.100533","DOIUrl":"10.1016/j.jcpo.2024.100533","url":null,"abstract":"<p><p>Biosimilars and generics have led to reduced cancer drug prices. The effect of biosimilar or generic drug competition on drug manufacturer revenue has not been previously described. In this study, the majority of top selling cancer drugs had a greater than 50 % decline in sales revenue within 2 years of generic or biosimilar market entry, reflecting both the decline in market share and reduction in unit drug price. This results in important drug manufacturer incentives, which may shape clinical trial agendas. The market structure incentives are unique for pharmaceutical companies due to the relatively short and limited duration of profitability. Policy changes such as patent reform leading to shorter duration of exclusivity may lead to greater incentive to expand low value indications in oncology.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100533"},"PeriodicalIF":2.0,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking public health in wartime: Smoking and long-term health outcomes amidst the war in Ukraine.","authors":"Paweł Koczkodaj, Irmina Maria Michalek","doi":"10.1016/j.jcpo.2024.100532","DOIUrl":"10.1016/j.jcpo.2024.100532","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100532"},"PeriodicalIF":2.0,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of conflict on cancer care in Libya.","authors":"Abeir El-Mogassabi, Ibtisam Gheith Kaziri","doi":"10.1016/j.jcpo.2024.100528","DOIUrl":"10.1016/j.jcpo.2024.100528","url":null,"abstract":"<p><strong>Background: </strong>The ongoing Libyan Civil Conflict, initiated in 2011, has had a devastating impact on the country's healthcare system, particularly cancer care. This review delves into the challenges faced by cancer patients and healthcare providers in Libya.</p><p><strong>Methods: </strong>A comprehensive literature review was conducted to identify relevant studies, reports, and news articles relating to cancer care in Libya. The review focused on the impact of the conflict on cancer prevention, diagnosis, treatment, and palliative care.</p><p><strong>Results: </strong>The conflict has significantly disrupted cancer care in Libya. Key challenges include limited access to care due to infrastructure damage and security concerns. Shortages of essential medications and medical equipment have hindered cancer treatment. Inadequate healthcare infrastructure, resulting from damage and destruction, limits the availability of diagnostic and treatment services. The shortage of skilled healthcare professionals exacerbates the situation. Additionally, the absence of reliable data on cancer incidence and mortality hinders effective planning and resource allocation.</p><p><strong>Policy summary: </strong>To improve cancer care in Libya, urgent action is needed to address the challenges posed by the conflict. This includes increasing investment in healthcare infrastructure, providing adequate funding for cancer control programmes, and strengthening the capacity of healthcare workers. Additionally, international cooperation and support are essential to help Libya rebuild its healthcare system and provide quality cancer care to its citizens.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100528"},"PeriodicalIF":2.0,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Financial conflicts among physician speakers at the April 12, 2024 Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?","authors":"Noah J Carr, Alyson Haslam, Vinay Prasad","doi":"10.1016/j.jcpo.2024.100529","DOIUrl":"10.1016/j.jcpo.2024.100529","url":null,"abstract":"<p><strong>Background: </strong>In April 2024, the Oncology Drug Advisory Committee (ODAC) voted to approve minimal residual disease (MRD) as a new regulatory endpoint for multiple myeloma (MM) despite its poor trial-level surrogacy. This is expected to result in faster MM drug approvals, a potential boon for the pharmaceutical companies that make them. This study investigates the prevalence of financial conflicts of interest (FCOIs) with these companies among United States (US)-based physician speakers at the meeting.</p><p><strong>Methods: </strong>Public data regarding the past 3 years of pharmaceutical company payments to US-based physician speakers at the ODAC meeting discussing MRD (available at https://openpaymentsdata.cms.gov/) were collected. For each general payment (GP), we recorded the amount, company payor, reason for payment, and associated products. Descriptive analyses were performed on payments from companies who manufacture MM therapeutics (MM payments).</p><p><strong>Results: </strong>12 of the 20 physician speakers (60 %) eligible to have FCOIs recorded on the OpenPayments database received MM payments from 2021 to 2023, totaling more than $792,200. A majority of both voting and non-voting members had MM payments (median $11,800 and $764), most of which were consulting fees. Speakers earned more than 3.7 times as much from GPs associated with MM-related products compared to those associated with non-MM-related products.</p><p><strong>Conclusion: </strong>Most US-based physician speakers at the April 2024 ODAC meeting had FCOIs from MM companies, including those with voting power.</p><p><strong>Policy summary: </strong>Our findings highlight the need for greater policing of FCOIs among US-based physicians involved in cancer drug regulatory policy.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100529"},"PeriodicalIF":2.0,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards promoting a legal framework for ending discrimination against cancer survivors. A human rights-centered approach.","authors":"Françoise Meunier, Grazia Scocca, Françoise Tulkens","doi":"10.1016/j.jcpo.2024.100527","DOIUrl":"10.1016/j.jcpo.2024.100527","url":null,"abstract":"<p><p>The article explores the development of the right to be forgotten (RTBF) for cancer survivors, with a focus on preventing discrimination based on their medical history. It discusses legal progress in European Union (EU) countries, including national laws and EU initiatives such as Europe's Beating Cancer Plan and the Consumer Credits Directive, which aim to protect survivors from financial and social obstacles. These measures are designed to standardize protection across member states and ensure that cancer survivors are not unfairly treated due to their past illness. The article advocates for continued progress in fully reintegrating cancer survivors into society, which involves eliminating the stigma associated with their medical history, and promoting justice, equality, and respect for their human dignity.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100527"},"PeriodicalIF":2.0,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic inequalities in kidney and renal pelvis cancer mortality in Canada: Trends over three decades.","authors":"Mohammad Hajizadeh, Nazanin Nasiri, Grace Johnston","doi":"10.1016/j.jcpo.2024.100524","DOIUrl":"10.1016/j.jcpo.2024.100524","url":null,"abstract":"<p><strong>Background: </strong>Kidney and renal pelvis cancer (KCa) presents significant health challenges that require investigation. This study measured and examined trends in socioeconomic inequalities in the mortality of KCa in Canada over the period 1990-2019.</p><p><strong>Methods: </strong>We constructed a census division level dataset pooled from the Canadian Vital Death Statistics Database (CVSD), the Canadian Census of the Population (CCP), and the National Household Survey (NHS) to measure income and education inequalities in the mortality rate of KCa in Canada over the study period. The age-standardized Concentration index (C), which measures inequality across all socioeconomic groups, was used to quantify income and education inequalities in the mortality of KCa in Canada. Trend analyses evaluated changes in these inequalities over time.</p><p><strong>Results: </strong>The average crude KCa mortality rates were found to be 5.97 and 3.40 per 100,000 for the male and female populations, respectively. The crude KCa mortality consistently increased over time in eastern but not western Canada. Statistically negative values of the age-standardized C index showed higher KCa mortality in the lower-income and less-educated population, particularly among females, with no changes observed over the 30-year study period.</p><p><strong>Conclusion: </strong>The higher KCa mortality in socioeconomically disadvantaged groups in Canada indicates the continuing need for primary prevention through lowering smoking rates, reducing obesity, and controlling hypertension. Additionally, promoting greater use of abdominal imaging for the incidental early KCa detection can enable more effective treatment and improved survival rates, especially for females of lower socioeconomic status.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100524"},"PeriodicalIF":2.0,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}